Recent studies found that TIGIT-blocking antibodies or TIGIT knockout potentiated anti-myeloma responses in mouse models, although this was primarily attributed to TIGIT expression suppressing the activation capacity of CD8+ T cells [45,46]. The gene discussed is TIGIT; the disease is plasma cell myeloma.